May 13, 2020: Prodrome Sciences is continuing operations during COVID-19. Our top priority is the safety and well-being of our employees, suppliers, and customers.

Alzheimer’s research published

April 25, 2019

Prodrome Sciences Inc. announces publication of peer-reviewed research paper linking high blood plasmalogen levels to lower risk of Alzheimer’s disease

Prodrome Sciences publishes research results from a community trial of 1,205 persons (average age = 84) that showed that elderly persons with high blood plasmalogens had a dramatically lower rate of dementia (6%) versus persons with low blood plasmalogens (31%).

In addition, it was observed that high blood plasmalogens was also associated with a lower risk of Alzheimer’s disease in persons with a high genetic risk of the disease. This is a critical observation because it shows that a person’s biochemical status affects their genetic risk for a disease, which means that it may be possible to correct genetic risk factors by targeting specific biochemical systems.

Click here to view the publication. Contact us for more information.

Keep in touch

©2021 Prodrome Sciences Inc.